决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Aggressive Cytotoxic Lymphomas of the Auricle: An Under-recognized Presentation.
Aggressive Cytotoxic Lymphomas of the Auricle: An Under-recognized Presentation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本系列包括 6 例细胞毒性淋巴瘤 NOS 和 4 例以耳部肿瘤为首发表现的 CD4+原发性皮肤γδ T 细胞淋巴瘤。
原发性皮肤肢端CD8+ T细胞淋巴增殖性疾病已被世界卫生组织认定为一个独立疾病实体,其特征为真皮内、非溃疡性结节,通常累及耳廓,并呈惰性病程。相比之下,以耳廓肿瘤性病变为表现的细胞毒性皮肤淋巴瘤可呈局部侵袭性或转移性病程。在本研究中,我们讨论这些未被充分认识、具有侵袭性的耳廓细胞毒性淋巴瘤的表现、诊断、分子特征及治疗选择。本系列纳入6例细胞毒性淋巴瘤NOS和4例以耳廓肿瘤为表现的CD4+原发性皮肤γδ T细胞淋巴瘤。在7例中观察到其他部位类似蕈样肉芽肿的斑片,免疫表型不一。尽管采用多模式治疗,10例患者中有7例在就诊后中位14个月内死亡。耳廓的坏死性和局部进展性肿瘤可能代表侵袭性、治疗难治性细胞毒性淋巴瘤的不祥征兆,其特征为迅速死亡。
Primary cutaneous acral CD8+ T-cell lymphoproliferative disorder has been recognized by the World Health Organization as a distinct entity characterized by dermal-based, nonulcerated nodules typically involving the auricle and following an indolent course. By contrast, cytotoxic cutaneous lymphomas presenting with tumoral lesions of the auricle can follow a locally aggressive or metastatic course. In this study, we discuss the presentation, diagnosis, molecular characteristics, and treatment options for these under-recognized, aggressive cytotoxic lymphomas of the auricle. Six cases of cytotoxic lymphoma NOS and 4 cases of CD4+ primary cutaneous γδ T-cell lymphoma that presented as auricular tumors were included in this series. Patches at other sites resembling mycosis fungoides with variable immunophenotypes were observed in 7 cases. Despite multimodal therapy, 7 of 10 patients died within median 14 months of presentation. Necrotizing and locally progressive tumors of the auricle may represent an ominous sign of aggressive treatment-refractory cytotoxic lymphomas characterized by swift mortality.
MEMBER ACCOUNT
登录成功会直接打开下一页。